501 AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426